Catalog Number
ACM217500964
Product Name
Tulathromycin A
Description
Tulathromycin A, also known as Tulathromycin and CP-472295, is a macrolide antibiotic used to treat bovine respiratory disease (BRD) in cattle and swine respiratory disease in pigs.
Synonyms
Tulathromycin; Draxxin; Tulathromycin A; CP-472,295; CP-472295; CP 472295; CP472295;
IUPAC Name
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-5-(propylaminomethyl)oxan-2-yl]oxy-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecan-15-one
Molecular Formula
C41H79N3O12
Canonical SMILES
O=C1[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@](CNCCC)(O)[C@](C)(OC)C2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3O)[C@](C)(O)C[C@@H](C)CN[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)O1
InChI
InChI=1S/C41H79N3O12/c1-15-17-42-22-41(50)28(8)53-31(20-39(41,10)51-14)55-33-25(5)35(56-37-32(45)29(44(12)13)18-24(4)52-37)38(9,48)19-23(3)21-43-27(7)34(46)40(11,49)30(16-2)54-36(47)26(33)6/h23-35,37,42-43,45-46,48-50H,15-22H2,1-14H3/t23-,24-,25+,26-,27-,28+,29+,30-,31+,32-,33+,34-,35-,37+,38-,39-,40-,41+/m1/s1
InChI Key
GUARTUJKFNAVIK-QPTWMBCESA-N
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Storage
Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Biological Target
Tulathromycin A (Tulathromycin), a macrolide antibiotic, inhibits protein synthesis (IC50=0.26 µM) by targeting bacterial ribosome.
Drug Formulation
This drug may be formulated in DMSO
Elemental Analysis
C, 61.09; H, 9.88; N, 5.21; O, 23.82
HS Tariff Code
2934.99.9001
In Vitro Activity
The immunomodulating mechanisms of the TUL activities were further analyzed in bovine cells in vitro. Tulathromycin inhibited the release of free fatty acids in bovine neutrophils stimulated with 10 μM melittin, an activator of PLA2. Furthermore, in both resting neutrophils and in those stimulated with 3 μM A23187, tulathromycin significantly reduced secreted levels of LTB4. The addition of 3 μM exogenous arachidonic acid partially restored the levels of LTB4 in tulathromycin-treated neutrophils.
Reference: Antimicrob Agents Chemother. 2014 Aug;58(8):4298-307. https://pubmed.ncbi.nlm.nih.gov/24820086/
In Vivo Activity
To investigate the direct anti-inflammatory actions of tulathromycin in the absence of a bacterial stimulus, calves were challenged intratracheally with zymosan, a known Toll-like receptor 2 (TLR2) ligand that has been used as an inflammatory stimulus in vivo. Three hours postchallenge, BAL fluid LTB4 levels were significantly higher in zymosan-challenged sham-treated calves than in control calves (mean ± standard deviation, 209.9 ± 60.5 pg/ml and 51.1 ± 13.1 pg/ml, respectively); tulathromycin abolished this increase in BAL fluid LTB4 levels (63.9 ± 16.0 pg/ml). Twenty-four hours postchallenge, the BAL fluid levels of PGE2 were significantly higher in calves challenged with zymosan versus in the controls (594.6 ± 134.5 pg/ml and 142.5 ± 59.2 pg/ml, respectively); tulathromycin treatment inhibited the increase in BAL fluid PGE2 levels caused by zymosan (148.3 ± 34.7 pg/ml).
Reference: Antimicrob Agents Chemother. 2014 Aug;58(8):4298-307. https://pubmed.ncbi.nlm.nih.gov/24820086/
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Stock Solution Storage
0-4 °C for short term (days to weeks), or -20 °C for long term (months).
Download
